GB201808575D0 - Methods for the treatment of psoriatic arthrits - Google Patents

Methods for the treatment of psoriatic arthrits

Info

Publication number
GB201808575D0
GB201808575D0 GBGB1808575.3A GB201808575A GB201808575D0 GB 201808575 D0 GB201808575 D0 GB 201808575D0 GB 201808575 A GB201808575 A GB 201808575A GB 201808575 D0 GB201808575 D0 GB 201808575D0
Authority
GB
United Kingdom
Prior art keywords
arthrits
psoriatic
treatment
methods
psoriatic arthrits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1808575.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Priority to GBGB1808575.3A priority Critical patent/GB201808575D0/en
Publication of GB201808575D0 publication Critical patent/GB201808575D0/en
Priority to MA052738A priority patent/MA52738A/fr
Priority to EP19726950.9A priority patent/EP3801548A1/en
Priority to JP2020565417A priority patent/JP2021524472A/ja
Priority to CA3101386A priority patent/CA3101386A1/en
Priority to KR1020207036941A priority patent/KR102955500B1/ko
Priority to US17/057,946 priority patent/US12329758B2/en
Priority to AU2019273664A priority patent/AU2019273664B2/en
Priority to CN201980034599.1A priority patent/CN112203660B/zh
Priority to PCT/EP2019/063283 priority patent/WO2019224283A1/en
Priority to JP2024021644A priority patent/JP7751362B2/ja
Priority to AU2025202777A priority patent/AU2025202777A1/en
Priority to US19/206,213 priority patent/US20260108530A1/en
Priority to JP2025157844A priority patent/JP2025183397A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1808575.3A 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits Ceased GB201808575D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits
PCT/EP2019/063283 WO2019224283A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis
US17/057,946 US12329758B2 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis
CN201980034599.1A CN112203660B (zh) 2018-05-24 2019-05-23 用于治疗银屑病关节炎的方法
JP2020565417A JP2021524472A (ja) 2018-05-24 2019-05-23 乾癬性関節炎の治療方法
CA3101386A CA3101386A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis
KR1020207036941A KR102955500B1 (ko) 2018-05-24 2019-05-23 건선성 관절염의 치료 방법
MA052738A MA52738A (fr) 2018-05-24 2019-05-23 Méthodes de traitement de l'arthrite psoriasique
AU2019273664A AU2019273664B2 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis
EP19726950.9A EP3801548A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis
JP2024021644A JP7751362B2 (ja) 2018-05-24 2024-02-16 乾癬性関節炎の治療方法
AU2025202777A AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis
US19/206,213 US20260108530A1 (en) 2018-05-24 2025-05-13 Methods for the treatment of psoriatic arthritis
JP2025157844A JP2025183397A (ja) 2018-05-24 2025-09-24 乾癬性関節炎の治療方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits

Publications (1)

Publication Number Publication Date
GB201808575D0 true GB201808575D0 (en) 2018-07-11

Family

ID=62812304

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1808575.3A Ceased GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits

Country Status (9)

Country Link
US (2) US12329758B2 (https=)
EP (1) EP3801548A1 (https=)
JP (3) JP2021524472A (https=)
CN (1) CN112203660B (https=)
AU (2) AU2019273664B2 (https=)
CA (1) CA3101386A1 (https=)
GB (1) GB201808575D0 (https=)
MA (1) MA52738A (https=)
WO (1) WO2019224283A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP4178616A4 (en) * 2020-07-13 2024-07-24 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044722A1 (en) 1999-01-29 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JPWO2004039816A1 (ja) 2002-10-29 2006-03-02 塩野義製薬株式会社 セフェム化合物の無機酸塩の結晶
CA2515190A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
EP1786811A2 (en) 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010013768A1 (ja) 2008-07-31 2010-02-04 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
AU2013279597B2 (en) 2012-06-22 2017-04-20 Alfasigma S.P.A. Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CA2982630A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
RS64677B1 (sr) 2015-04-13 2023-11-30 Galapagos Nv Metode lečenja kardiovaskularnih poremećaja
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
PL3595667T3 (pl) * 2017-03-14 2024-03-18 Galapagos Nv Kompozycje farmaceutyczne zawierające inhibitor jak

Also Published As

Publication number Publication date
JP7751362B2 (ja) 2025-10-08
AU2019273664B2 (en) 2025-01-23
EP3801548A1 (en) 2021-04-14
KR20210013168A (ko) 2021-02-03
CN112203660A (zh) 2021-01-08
MA52738A (fr) 2021-04-14
US12329758B2 (en) 2025-06-17
CN112203660B (zh) 2024-12-31
AU2019273664A1 (en) 2021-01-21
US20210299135A1 (en) 2021-09-30
WO2019224283A1 (en) 2019-11-28
JP2025183397A (ja) 2025-12-16
JP2021524472A (ja) 2021-09-13
JP2024069223A (ja) 2024-05-21
US20260108530A1 (en) 2026-04-23
AU2025202777A1 (en) 2025-05-08
CA3101386A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL276917A (en) A process for the preparation of alubixivet
SG11202104461XA (en) Therapeutic methods
IL275482A (en) Asketamine for the treatment of depression
IL291735A (en) Heteroarylbiphenylamines for the treatment of pd-l1 diseases
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL283948A (en) Methods for treating depression
IL286000A (en) Asketamine for the treatment of depression
GB201813876D0 (en) Treatment
SG10202012106WA (en) Methods for treating inflammatory conditions of the lungs
GB201800546D0 (en) Treatment
PL3765440T3 (pl) Sposób wytwarzania n-alkilonitratoetylonitroamin
IL270819A (en) Methods for treating chronic paucity
IL287213A (en) Methods for treating patients with psoriatic arthritis
IL281254A (en) A process for the preparation of lanbatinib
SG11202102827YA (en) Treatment methods
SG11202102878TA (en) Treatment methods
HUE049463T2 (hu) Eljárás kavicsok kezelésére
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
ZA202001536B (en) Method for the treatment of wastewaters
SG11202011434SA (en) Methods for the treatment of bladder cancer
PL3599256T3 (pl) Sposób wytwarzania poliorganosiloksanów
IL269681A (en) New methods for treating multiple sclerosis
HUP1800278A2 (en) Process for the preparation of boc-linagliptin
GB201917487D0 (en) Methods for the treatment of retinoblastoma

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)